Not rendering correctly? View this email as a web page here.

- Q3 2018 -


Introducing the Fall 2018 FAST Companies

Read More


  • SciBac (FAST Fall 2016): CLSI FAST Graduate Wins up to $3.76M from CARB-X | Read More
  • MicroSynbiotiX (FAST Fall 2017) shows feasibility of their microalgae platform to deliver oral vaccines to fish | Read More
  • FAST grad (Fall 2017) Pheronym was awarded a $500,000 USDA-AFRI (United States Department of Agriculture – Agriculture and Food Research Initiative) research grant to expand their breakthrough nematode bio-remediation technology to other nematode species | Read More
  • FAST grad (Spring 2015) Magnetic Insight received NIH award of $1.5M Phase II SBIR grant to support the first commercial multimodal preclinical magnetic particle imaging system | Read More
  • Ligandal (FAST Spring 2016) listed in top 9 CRISPR startup companies changing the future of biotech and medicine | Read More
  • FAST grad (Fall 2013) Xcell Biosciences announced a collaboration with Carolina BioOncology Institute to further pre-clinical development of true personalized medicine therapies | Read More
  • CLSI and CTIC Capital are joining forces to present a conference on September 30 pairing early and mid-stage therapeutics companies with Chinese investors. If interested please visit: and Register Here

About FAST Advisory Program

The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a twelve-week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.

For information on the FAST program, contact Julie Harness at

Upcoming Events & Key Dates
9/13  Digital Therapeutics and the Future of Medicine, South San Francisco Register Here
9/13 IP Piracy in Life Science: Threat Landscape and Defensive Tactics, UCSF Mission Bay Register Here
9/14 Skin Microbiome: NextGen Opportunities, San Diego Register Here
9/18 Bisnow: San Diego Life Sciences & Healthcare 2018 Register Here
9/20 The Secret Science of Storytelling, South San Francisco Register Here
9/21 MDMA 2018 Medical Technology Executive Forum, Palo Alto Register Here
9/25 QB3 SBIR Fall Workshop: Get non-dilutive funding for your startup, San Francisco Register Here for Berkeley Register Here
9/25 What, Why, Where, When and How to Hold Your First-In-Human Trial, San Diego Register Here
9/26 Better Together: Managing Term Sheets for a Successful Collaboration, San Diego Register Here
9/30 CTIC Cross-Border Healthcare Symposium, San Francisco Register Here
10/1, 11/5, 2/4, 3/4, 4/1 Leadership EDGE for Women, South San Francisco Register Here
10/1-3 SynBioBeta 2018: The Global Synthetic Biology Summit, San Francisco Register Here
10/4 Intro to Immunogenicity: Keys to Safe and Effective Drug Development, JLabs, South San Francisco Register Here
10/4 CLSA Bio on the Bay with ARE, San Francisco Register Here
10/9 MedImmune California Translational Science Forum: Patient Centric Drug Development in the Digital Era, San Francisco Register Here
10/9 CLSI FAST & Fellows Networking Happy Hour, South San Francisco Register Here
10/17 CLSI Innovation Series: Expand your Phase I Clinical Trial, South San Francisco Register Here
10/17-18 BIO Investor Forum, San Francisco Register Here
10/30 Rosenman D-Series: Market Strategy with Sanaz Saatchi of Crownpoint Medical, San Francisco Register Here
11/10 Deadline to submit for the 4th Annual Jumpstart Grant. Contact Cathi Rogers for more details: Email: Winners will be announced Dec
11/30 Annual Pantheon 2018, San Francisco Register Here
12/11 Rosenman D-Series: The First Dollar: Strategies and Ethics of Seed-Stage Fundraising, San Francisco Register Here



  • Powered by CARB-X company, Talis Biomedical was awarded a $5.6M grant from NIAID/NIH to fund the development of a clinically impactful Point-of-Care diagnostics for antimicrobial resistant bacteria | Read More
  • Powered by CARB-X company, Achaogen announced the FDA approved ZEMDRI™ (plazomicin) for adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Enterobacteriacea in patients who have limited or no alternative treatment options | Read More
  • Powered by CARB-X company, T2 Biosystems featured in STAT News article: Sepsis is the third leading cause of death. Can a new blood test change that? | Read More
  • Powered by CARB-X company, Antabio SAS announced it has extended its Series A financing round with an additional €5.2 million with new investors BNP Paribas Development and Sham Innovation Santé, and from existing shareholder Galia Gestion | Read More
  • Powered by CARB-X company, Spero Therapeutics announced that it was awarded up to $54.2 million from BARDA and DTRA to support the development of SPR994, an oral carbapenem for the treatment of complicated urinary tract infections | Read More
  • Powered by CARB-X company, BugWorks raised $9M Series A funding to take its first-in-class antibiotic into the clinic | Read More
  • CARB-X awards up to $4.5 million to Summit Therapeutics to support the development of a new class of antibiotic compounds addressing a novel target to treat gonorrhea Read More Shortly after, Summit also announced it has been awarded an additional $12 million under its contract with BARDA for Phase 3 development program of ridinilazole for the treatment of C. difficile infection | Read More

Other AMR News

  • The Department of Health and Social Care announced the launch of a £10 million research competition to fund innovations to tackle antimicrobial resistance (AMR) in humans | Read More
  • Bay Area and Boston-based start-up Arc Bio is launching a proprietary antimicrobial resistance software, Galileo™ AMR to identify and annotate gram-negative bacteria antimicrobial resistance in less than five minutes | Read More
  • As Novartis terminates its antibacterial research at its Novartis Institutes for Biomedical Research (NIBR) campus, who will make new antibiotics? | Read More

 About CARB-X


CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. With more than $500 million to invest, CARB-X funds the best science from around the world. The CARB-X portfolio is the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products to prevent and treat life-threatening bacterial infections. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI).

For more information on CARB-X, please contact Amy Xu at

Upcoming Events
9/17 NIAID Workshop – Science and Regulation of Live Microbiome-Based Products Used to Prevent, Treat, or Cure Diseases in Humans, Rockville Register Here
10/3-7 ID Week 2018, San Francisco  Register Here
10/6-14 International Course on Antibiotics and Resistance, France Register Here
11/7-9 Better Methods for Clinical Studies in Infectious Diseases and Clinical Microbiology: A Hands on Workshop, Spain Register Here
11/29-30 British Society Antimicrobial Chemotherapy: Antibiotic Resistance Mechanisms Workshop for Researchers, UK Register Here


 STEM Education & Careers 

  • CLSI Unveils Women Leading Life Sciences Initiative Read More | Read More
  • NexGeneGirls Concludes Science Summer Academy for Young Females of Color Read More | Read More
  • East Bay STEM Network Releases Early Math Policy Recommendations | Read More
  • Biotech Primer Article: Rare Disease Focus: PKU | Read More

About CLSI Education & Career Programs

CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.

Upcoming Events
9/20-21 BioBasics: Biotech for the Non-Scientist, South San Francisco Register Here
10/10 Women Leading Life Sciences: Advance Your Career Through Mentorship, South San Francisco Register Here
10/11-12 Drug Development Immersion, South San Francisco Register Here
12/5-6 Drug Development Immersion, San Diego Register Here
12/13-14 BioBasics: Biotech for the Non-Scientist, South San Francisco Register Here



California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. Our mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI also serves as an accelerator for CARB-X, the world’s largest public-private partnership devoted to early stage antibacterial R&D.

CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California’s leading life sciences organizations. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute.